Last year, the company reported earnings of $2.11 per share on revenue of $2.1 billion for the 2014 third quarter. The stock has a 50 day moving average price of $203.20 and a 200-day moving average price of $222.59. BMO Capital Markets reaffirmed a “buy” rating on shares of Valeant Pharmaceuticals Intl in a report on Friday, June 26th.
Advertisement
Canaccord Genuity reissued their buy rating on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) in a report released on Sunday morning, AnalystRatings.NET reports.
Sales grew from $2.06 billion year-over-year to $2.79 billion, beating analysts’ estimate of $2.78 billion.
The company tripled the price of its heart drug Isuprel and raised the price six-fold for another heart drug, Nitropress, after buying them in February.
Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 177.56 on Friday. Finally, Zacks upgraded shares of Valeant Pharmaceuticals Intl from a hold rating to a buy rating and set a $288.00 price objective for the company in a research note on Tuesday, July 28th.
A number of equities analysts have weighed in on the company.
Up to Friday’s close, Valeant’s U.S.-listed stock had fallen about 27 percent since Sept 21 when Clinton tweeted her intent to tackle high prices in a few drug markets. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, Farmer Ronald Harold, director of Valeant Pharmaceuticals global, Inc., executed a transaction worth $110,000 on August 26, 2015. Net income attributable to Valeant Pharma was $49.5 million or $0.14 per share compared to $275.4 million or $0.81 per share, last year. Valeant Pharmaceuticals had estimated earnings of $2.60 to $2.70 per share on revenue of $2.6 billion to $2.8 billion.
In other Valeant Pharmaceuticals Intl news, CFO Robert L. Rosiello acquired 7,875 shares of the business’s stock in a transaction dated Friday, July 31st. The company’s revenue was up 35.5% compared to the same quarter previous year. A total of 500 shares were purchased at an average price of $220.
Advertisement
Valeant Pharmaceuticals global, Inc., formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products. The Company is engaged in developing, manufacturing, and marketing a wide selection of branded, generic and branded generic pharmaceuticals, over the counter (NYSE:VRX) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are promoted directly or indirectly in over 100 nations. The Firm operates through two divisions: developed markets and emerging markets. The Company’s developed markets segment includes sales in the U.S. of OTC goods pharmaceutical products, and medical device products. Within its U.S. Dermatology segment and Branded Generic – Europe segment the Company generates service revenue from contract services in the areas of dermatology and topical medication.
